Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Chinese Journal of Laboratory Medicine ; 43(3):230-233, 2020.
Article | WHO COVID | ID: covidwho-769462

ABSTRACT

Objective: To investigate the diagnostic value of immunoglobulin M (IgM) and immunoglobulin G(IgG) antibodies to 2019 Novel Coronavirus (2019-nCoV) in 2019-nCoV infection Methods: This is a retrospective study Serum samples were collected from 284 patients including outpatients and inpatients in the Renmin Hospital of Wuhan University from January 20 to February 17 in 2020 Among them 205 cases were 2019-nCoV infected patients, including 186 cases confirmed with nucleic acid test and 19 cases diagnosed by clinical symptoms and CT characteristics according to "the New Coronavirus Pneumonia Control Protocol (5th edition)" A total of 79 subjects with other diseases but negative to 2019-nCoV infection were recruited as control group Serum IgM and IgG antibodies to 2019-nCoV were measured with fully automated immunoassay technology for all subjects Statistical significance between 2019-nCoV antibodies test and 2019-nCoV nucleic acid test was determined using the χ2 tests Results: The sensitivity of serum IgM and IgG antibodies to 2019-nCoV were 70 24%(144/205) and 96 10%(197/205) respectively and the specificity were 96 20%(76/79) and 92 41%(73/79) respectively The positive and negative predictive values of 2019-nCoV antibodies were 95 63%(197/206) and 91 03% (71/78) respectively, and the positive and negative predictive values of 2019-nCoV nucleic acid test were 100%(186/186) and 80 61%(79/98) respectively The total coincidence rate of diagnosing 2019-nCoV infection between antibody tests and nucleic acid test for 2019-nCoV were 88 03%(250/284) Conclusion: Joint detection of serum IgM and IgG antibodies to 2019-nCoV is an effective screening and diagnostic indicators for 2019-nCoV infection, and an effective complement to the false negative results to nucleic acid test

2.
Chinese Journal of Laboratory Medicine ; 43(3):209-212, 2020.
Article | WHO COVID | ID: covidwho-769460

ABSTRACT

In December, the outbreak of a novel coronavirus (2019-nCoV) in Wuhan, China, has attracted extensive global attention On January 20, 2020, the Chinese health authorities upgraded the coronavirus to a Class B infectious disease in the Law of the People's Republic of China on the Prevention and Treatment of Infectious Diseases, and considered it as Class A infectious diseases in disease control and prevention On January 18, 2020, the 2019-nCoV nucleic acid detection test was listed as the diagnostic criteria in the "guidelines for diagnosis and treatment of pneumonia due to 2019-nCoV (Trial Version 2)" Therefore, standardizing the operation process of the 2019-nCoV nucleic acid detection in clinical laboratories has become a top priority It is of paramount importance to establish standard protocols for detection of the 2019-nCoV nucleic acids in clinical laboratories to improve the reliability of the results and ensure the biosafety of laboratory personnel

3.
Chinese Journal of Laboratory Medicine ; 43(4):341-345, 2020.
Article | WHO COVID | ID: covidwho-769446

ABSTRACT

Objective: To investigate the positive rate for 2019-nCoV tests and co-infections in Wuhan district Methods: A total of 8 274 cases in Wuhan were enrolled in this cross-sectional study during January 20 to February 9 in 2020, and were tested for 2019-nCoV using fluorescence quantitative PCR Both respiratory tract samples (nasopharynx, oropharynx, sputum and alveolar lavage fluid) and non-respiratory tract samples (urine, feces, anal swabs, blood and conjunctival sac swabs) were collected If both orf1ab and N genes are positive, they are classified as nucleic acid test positive group;if both orf1ab and N genes are negative, they are classified as negative group;if single gene target is positive, they are classified as suspicious group Individuals were divided into male group and female group according to sex At the same time, 316 patients were tested for 13 respiratory pathogens by multiplex PCR Results: Among the 8 274 subjects, 2 745 (33 17%) were 2019-nCoV infected;5 277 (63 77%) subjects showed negative results in the 2019-nCoV nucleic acid test;and 252 cases (3 05%) was not definitive (inconclusive result) The age of cases with COVID-19 patients and inconclusive cases was significantly higher than that of cases without 2019-nCoV infection (56>40, t=27 569, P40, t=6 774, P<0 001) The positive rate of 13 respiratory pathogens multiple tests was significantly lower in 104 subjects who were positive for 2019-nCoV compared with those in subjects who were negative for 2019-nCoV test (5 77% vs 18 39%, χ2=24 105, P=0 003) Four types of respiratory tract samples and five types of non-respiratory tract sampleswere found to be positive for 2019-nCoV nucleic acid test Conclusion: The 2019-nCoV nucleic acid positive rate inmale is higher than infemale Co-infections should be pay close attention in COVID-19 patients 2019-nCoV nucleic acid can be detected in non-respiratory tract samples

4.
Eur Rev Med Pharmacol Sci ; 24(14): 7855-7860, 2020 07.
Article in English | MEDLINE | ID: covidwho-693645

ABSTRACT

We present the case details of seven patients diagnosed with severe novel coronavirus disease 2019 (2019-nCoV, hereafter COVID-19) with hepatic injury. Most of these patients were elderly and had hypertension, diabetes mellitus, coronary heart disease, and other underlying health conditions prior to admission for COVID-19. Liver injury occurred in all seven cases during the course of the disease. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels initially increased (1.2-times to 2.0-times the normal value, respectively) in the second week. The liver function recovered in all patients within one week of conventional liver protection treatment. Elevated serum transaminase levels in these patients were due to the COVID-19 infection but could also be related to systemic immune response caused by cytokine storm syndrome (CSS) and hepatocyte damage caused by ischemia and hypoxia. COVID-19 is highly infectious and mainly affects the lungs. In some cases, especially in patients with severe disease type, COVID-19 may also cause liver injury. The liver function of patients with severe COVID-19 should be very carefully monitored, especially if the patients are elderly and have underlying comorbidities.


Subject(s)
Coronavirus Infections/pathology , Liver Diseases/diagnosis , Pneumonia, Viral/pathology , Aged , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Betacoronavirus/isolation & purification , Coronary Disease/complications , Coronavirus Infections/complications , Coronavirus Infections/immunology , Coronavirus Infections/virology , Female , Humans , Hypertension/complications , Liver Diseases/etiology , Lung/diagnostic imaging , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/immunology , Pneumonia, Viral/virology , Severity of Illness Index , Tomography, X-Ray Computed
6.
Pharmazie ; 75(5): 161-163, 2020 05 01.
Article in English | MEDLINE | ID: covidwho-251922

ABSTRACT

Since December 2019, numerous cases of coronavirus disease 2019 (COVID-19) caused by the infection of the novel coronavirus (2019-nCoV) have been confirmed in Wuhan, China. The outbreak of 2019-nCoV in China embodied a significant and urgent threat to global health. 2019-nCoV was a new, highly contagious coronavirus discovered following the outbreak of SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-CoV). The novel coronavirus can cause severe respiratory disease and even death. However, no specific therapeutic drugs have been developed clinically thus far. This article examines the potential of therapeutic drugs by assessing the structure of 2019-nCoV, its mechanism in invading host cells, and the anti-viral mechanism of the human autoimmune system. We also review the latest research regarding the progress of potential therapeutic drugs and provide references for new drug developments of COVID-19.


Subject(s)
Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Antibodies, Neutralizing/pharmacology , Antibodies, Viral/immunology , Antiviral Agents/pharmacology , Betacoronavirus , Humans , Medicine, Chinese Traditional , Pandemics , Peptidyl-Dipeptidase A , Spike Glycoprotein, Coronavirus/antagonists & inhibitors , Viral Proteins/antagonists & inhibitors
8.
Ann Oncol ; 31(7): 894-901, 2020 07.
Article in English | MEDLINE | ID: covidwho-16011

ABSTRACT

BACKGROUND: Cancer patients are regarded as a highly vulnerable group in the current Coronavirus Disease 2019 (COVID-19) pandemic. To date, the clinical characteristics of COVID-19-infected cancer patients remain largely unknown. PATIENTS AND METHODS: In this retrospective cohort study, we included cancer patients with laboratory-confirmed COVID-19 from three designated hospitals in Wuhan, China. Clinical data were collected from medical records from 13 January 2020 to 26 February 2020. Univariate and multivariate analyses were carried out to assess the risk factors associated with severe events defined as a condition requiring admission to an intensive care unit, the use of mechanical ventilation, or death. RESULTS: A total of 28 COVID-19-infected cancer patients were included; 17 (60.7%) patients were male. Median (interquartile range) age was 65.0 (56.0-70.0) years. Lung cancer was the most frequent cancer type (n = 7; 25.0%). Eight (28.6%) patients were suspected to have hospital-associated transmission. The following clinical features were shown in our cohort: fever (n = 23, 82.1%), dry cough (n = 22, 81%), and dyspnoea (n = 14, 50.0%), along with lymphopaenia (n = 23, 82.1%), high level of high-sensitivity C-reactive protein (n = 23, 82.1%), anaemia (n = 21, 75.0%), and hypoproteinaemia (n = 25, 89.3%). The common chest computed tomography (CT) findings were ground-glass opacity (n = 21, 75.0%) and patchy consolidation (n = 13, 46.3%). A total of 15 (53.6%) patients had severe events and the mortality rate was 28.6%. If the last antitumour treatment was within 14 days, it significantly increased the risk of developing severe events [hazard ratio (HR) = 4.079, 95% confidence interval (CI) 1.086-15.322, P = 0.037]. Furthermore, patchy consolidation on CT on admission was associated with a higher risk of developing severe events (HR = 5.438, 95% CI 1.498-19.748, P = 0.010). CONCLUSIONS: Cancer patients show deteriorating conditions and poor outcomes from the COVID-19 infection. It is recommended that cancer patients receiving antitumour treatments should have vigorous screening for COVID-19 infection and should avoid treatments causing immunosuppression or have their dosages decreased in case of COVID-19 coinfection.


Subject(s)
Betacoronavirus , Coronavirus Infections/diagnostic imaging , Coronavirus Infections/epidemiology , Hospitalization/trends , Neoplasms/diagnostic imaging , Neoplasms/epidemiology , Pneumonia, Viral/diagnostic imaging , Pneumonia, Viral/epidemiology , Aged , China/epidemiology , Cohort Studies , Coronavirus Infections/therapy , Female , Humans , Male , Middle Aged , Neoplasms/therapy , Pandemics , Pneumonia, Viral/therapy , Retrospective Studies
9.
Zhonghua Wai Ke Za Zhi ; 58(3): 170-177, 2020 Mar 01.
Article in Chinese | MEDLINE | ID: covidwho-9956

ABSTRACT

The 2019 coronavirus disease(COVID-19) is a highly infectious disease, has a long incubation period and a variety of clinical manifestations, which has a significant impact on public health and life. Afterwards, scientific and standardized work processing during the epidemic is of great significance for prevention and control. In order to implement the central government's decision-making deployment and defeat the COVID-19 as soon as possible, we had focused on the key points in the clinical work of general surgery according to latest relevant guidelines, literature and experience in epidemic prevention. Finally, we drafted the prevention and control strategies and recommendations to make a reference for medical staff of general surgery to fight against COVID-19.


Subject(s)
Betacoronavirus , Coronavirus Infections , General Surgery/standards , Pneumonia, Viral , China , Humans , Practice Guidelines as Topic
10.
Zhonghua Wai Ke Za Zhi ; 58(0): E001, 2020 Feb 14.
Article in Chinese | MEDLINE | ID: covidwho-911

ABSTRACT

Novel coronavirus pneumonia (NCP) is a highly infectious disease, has a long incubation period and a variety of clinical manifestations, which has a significant impact on public health and life. Afterwards, scientific and standardized work processing during the epidemic is of great significance for prevention and control. In order to implement the central government's decision-making deployment and defeat the NCP as soon as possible, we had focused on the key points in the clinical work of general surgery according to latest relevant guidelines, literature and experience in epidemic prevention. Finally, we drafted the prevention and control strategies and recommendations to make a reference for medical staff of general surgery to fight NCP.

SELECTION OF CITATIONS
SEARCH DETAIL